226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05737121 (ClinicalTrials.gov) | March 7, 2023 | 10/2/2023 | Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: VNX001;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Vaneltix Pharma, Inc. | Prevail Infoworks, Inc | Not yet recruiting | 18 Years | N/A | All | 120 | Phase 2 | United States |
| 2 | NCT04734106 (ClinicalTrials.gov) | March 2023 | 27/1/2021 | Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, Freeze-Dried Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | Interstitial Cystitis;Chronic Interstitial Cystitis;Bladder Pain Syndrome | Drug: Desert Harvest Aloe Vera Capsules;Other: Placebo Capsules | Wake Forest University Health Sciences | Desert Harvest | Not yet recruiting | 18 Years | N/A | All | 100 | Early Phase 1 | United States |
| 3 | NCT05740007 (ClinicalTrials.gov) | March 2023 | 13/2/2023 | Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: IW-3300 rectal foam;Drug: Placebo | Ironwood Pharmaceuticals, Inc. | NULL | Recruiting | 18 Years | 70 Years | All | 300 | Phase 2 | United States |
| 4 | NCT05726786 (ClinicalTrials.gov) | March 2023 | 16/1/2023 | The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial) | The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial) | Bladder Cancer;Interstitial Cystitis;Painful Bladder Syndrome;Neurogenic Bladder;Hemorrhagic Cystitis;Endometriosis;Bladder Disease | Drug: Immunonutrition | Centre Hospitalier Universitaire Vaudois | University Hospital Inselspital, Berne;Hôpital Riviera-Chablais, Vaud-Valais | Not yet recruiting | 18 Years | N/A | All | 232 | Phase 3 | Switzerland |
| 5 | NCT05062902 (ClinicalTrials.gov) | January 1, 2023 | 16/9/2021 | A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management | An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management | Interstitial Cystitis;Chronic Pain;Pelvic Floor; Relaxation;Pelvic Floor Disorders | Device: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device;Drug: Botulinum Neurotoxin | HillMed Inc. | Baylor College of Medicine;University of Houston | Not yet recruiting | 18 Years | 60 Years | Female | 46 | Early Phase 1 | United States |
| 6 | NCT05658874 (ClinicalTrials.gov) | December 1, 2022 | 23/11/2022 | A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain | A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain | Interstitial Cystitis | Drug: Multimodal Bundle Drugs;Procedure: Operative Cystoscopy;Behavioral: Behavioral health consultation/therapy;Other: Pelvic floor physical therapy;Other: Usual Urogynecologic care;Drug: Bladder Instillation;Drug: Vaginal estrogen;Drug: Methenamine;Drug: Amitriptyline/Gabapentin | Jocelyn Fitzgerald | NULL | Recruiting | 18 Years | 99 Years | Female | 80 | Phase 3 | United States |
| 7 | NCT05141006 (ClinicalTrials.gov) | March 29, 2022 | 19/11/2021 | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Arm Study to Assess the Safety and Efficacy of a Single Treatment of BOTOX, Followed by an Optional Open-Label Treatment With BOTOX, in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Drug: BOTOX;Drug: Placebo for BOTOX | Allergan | NULL | Recruiting | 18 Years | 75 Years | Female | 80 | Phase 2 | United States;Canada |
| 8 | JPRN-jRCTs051210106 | 13/10/2021 | 13/10/2021 | ESTOC study | The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial - ESTOC study | Interstitial cystitis bladder, inflammation, pain;D018856 | Participants will be randomly assigned to splatast group or control group. In splatast group, splatast tosilate capsule 100 mg (1 capsule at a time) will be orally administered 3 times a day between meals for 3 months. In control group, flavoxate hydrochloride tablets 200 mg (1 tablet at a time) will be orally administered 3 times a day between meals for 3 months. | Torimoto Kazumasa | Fujimoto Kiyohide | Recruiting | >= 20age old | Not applicable | Both | 100 | Phase 2 | Japan |
| 9 | ChiCTR2100051474 | 2021-09-15 | 2021-09-24 | Urinary Galectin-3 and CXCL-7 as biomarkers for diagnosing interstitial cystitis and correlation with clinical characteristics | Urinary Galectin-3 and CXCL-7 as biomarkers for diagnosing interstitial cystitis and correlation with clinical characteristics | interstitial cystitis | Gold Standard:Suprapubic pain, pressure or discomfort, pressure, or discomfort related to bladder filling, accompanied by urgency, frequency, etc., for more than 6 months.;Index test:Both interstitial cystitis patients with or without Hunner’s ulcers were recruited in the study, while healthy subjects were involved as controls. Then we collected urine samples from all the involved subjects, and the CXCL-7 level and Galectin-3 level in the supernatants of urine were measured by ELISA. ; | Hebei People's Hospital | NULL | Pending | Both | Target condition:50;Difficult condition:50 | China | |||
| 10 | NCT05147779 (ClinicalTrials.gov) | September 12, 2021 | 29/11/2021 | Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis | Erectile Dysfunction;Peyronie's Disease;Interstitial Cystitis | Biological: AlloRx | The Foundation for Orthopaedics and Regenerative Medicine | NULL | Recruiting | N/A | N/A | All | 20 | Phase 1 | Antigua and Barbuda |
| 11 | NCT04313972 (ClinicalTrials.gov) | September 7, 2021 | 16/3/2020 | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial | Interstitial Cystitis;Painful Bladder Syndrome;Bladder Pain Syndrome;Low Dose Naltrexone;Low-dose Naltrexone;Naltrexone | Drug: low-dose naltrexone;Drug: Placebo oral tablet | NorthShore University HealthSystem | NULL | Recruiting | 18 Years | 110 Years | Female | 44 | Phase 4 | United States |
| 12 | NCT05275647 (ClinicalTrials.gov) | May 18, 2021 | 13/1/2022 | Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis | Therapeutic Efficacy and Safety of Low Energy Shock Wave (LESW) Plus Botulinum Toxin A Instillation in Treatment of Patients With Interstitial Cystitis Refractory to Conventional Therapy - A Clinical and Immunohistochemistry Study | Interstitial Cystitis | Drug: BOTOX 100U in normal saline;Drug: Normal saline | Buddhist Tzu Chi General Hospital | Ministry of Science and Technology, Taiwan;Hualien Tzu Chi General Hospital | Recruiting | 20 Years | N/A | All | 75 | Phase 2 | Taiwan |
| 13 | NCT04349930 (ClinicalTrials.gov) | January 2021 | 13/4/2020 | The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) | The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) | Interstitial Cystitis;Bladder Pain Syndrome | Drug: Cannabidiol vaginal suppository;Drug: Placebo vaginal suppository | University of New Mexico | NULL | Withdrawn | 18 Years | N/A | Female | 0 | Phase 1 | United States |
| 14 | NCT04610359 (ClinicalTrials.gov) | October 20, 2020 | 19/10/2020 | Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis | Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis; Open-labelled, Single Center, Phase 1 Study | Interstitial Cystitis;Stem Cell Transplant;Mesenchymal Stem Cell | Drug: MR-MC-01 | Asan Medical Center | MIRAE CELL BIO | Recruiting | 20 Years | N/A | Female | 3 | Phase 1 | Korea, Republic of |
| 15 | NCT04447729 (ClinicalTrials.gov) | October 15, 2020 | 10/6/2020 | A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome | A Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Female Patients With Interstitial Cystitis-Bladder Pain Syndrome | Interstitial Cystitis | Drug: fremanezumab | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Withdrawn | 18 Years | N/A | Female | 0 | Phase 2 | NULL |
| 16 | NCT04401176 (ClinicalTrials.gov) | September 15, 2020 | 19/5/2020 | Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome | A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A | Walter Reed National Military Medical Center | NULL | Active, not recruiting | 18 Years | N/A | Female | 58 | Phase 2 | United States |
| 17 | NCT04208087 (ClinicalTrials.gov) | March 30, 2020 | 25/11/2019 | PK and Safety of SI-722 in IC/BPS | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of SI-722 Intravesical Instillation in Interstitial Cystitis/Bladder Pain Syndrome Subjects | Interstitial Cystitis;Bladder Pain Syndrome | Drug: SI-722;Drug: Placebo | Seikagaku Corporation | NULL | Completed | 18 Years | 80 Years | All | 33 | Phase 1/Phase 2 | United States |
| 18 | NCT04789135 (ClinicalTrials.gov) | March 20, 2020 | 1/3/2021 | Evaluation of Response to Use of Intravesical Ozone Gas in Interstitial Cystitis /Bladder Pain Syndrome | Evaluation of Response to Use of Intravesical Ozone Gas in Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis, Chronic;Bladder Pain Syndrome | Drug: Ozone | Anhembi Morumbi University | NULL | Active, not recruiting | N/A | N/A | Female | 50 | Phase 2 | Brazil |
| 19 | NCT03844412 (ClinicalTrials.gov) | November 4, 2019 | 15/2/2019 | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia;Temporomandibular Disorder;Fibromyalgia Syndrome;Irritable Bowel Syndrome;Migraines;Tension Headache;Endometriosis;Interstitial Cystitis;Back Pain;Chronic Fatigue Syndrome | Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Drug: Nortriptyline;Drug: Placebo cream;Drug: Placebo pill | Duke University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 18 Years | 50 Years | Female | 400 | Phase 2 | United States |
| 20 | NCT04821882 (ClinicalTrials.gov) | May 1, 2019 | 25/3/2021 | Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis | Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis | Bladder Pain Syndrome;Interstitial Cystitis | Drug: Dextrose | National Defense Medical Center, Taiwan | NULL | Completed | 20 Years | N/A | All | 29 | N/A | Taiwan |
| 21 | NCT04118946 (ClinicalTrials.gov) | March 20, 2019 | 2/10/2019 | Platelet Enriched Plasma for Treatment of Interstitial Cystitis | Intra Vesical Instillation Versus Submucosal Injection of Platelet Enriched Plasma for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: A Randomized Controlled Trial | Interstitial Cystitis;Bladder Pain Syndrome;Platelet Enriched Plasma | Biological: platelet enriched plasma | Mansoura University | NULL | Recruiting | 18 Years | N/A | Female | 33 | Phase 1/Phase 2 | Egypt |
| 22 | NCT03463915 (ClinicalTrials.gov) | January 25, 2019 | 28/2/2018 | Clinical Trial Comparing Two Bladder Instillations for IC/BPS | Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: Bladder instillation WITH triamcinolone acetonide;Drug: Bladder instillation WITHOUT triamcinolone acetonide | Olivia Cardenas-Trowers, M.D. | NULL | Completed | 18 Years | N/A | Female | 90 | Phase 3 | United States |
| 23 | NCT03844581 (ClinicalTrials.gov) | January 1, 2019 | 15/2/2019 | Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis | Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis | Interstitial Cystitis | Device: interferential current;Drug: Propiverine Hydrochloride | Cairo University | NULL | Completed | 25 Years | 40 Years | Female | 40 | N/A | Egypt |
| 24 | NCT03523559 (ClinicalTrials.gov) | March 31, 2018 | 1/5/2018 | Genetic and Histopathologic Characteristics of Interstitial Cystitis | Genetic and Histopathologic Characteristics of Interstitial Cystitis | Interstitial Cystitis | Genetic: bladder tissue of Interstitial Cystitis and normal bladder tissue | Samsung Medical Center | NULL | Recruiting | 19 Years | N/A | All | 15 | Korea, Republic of | |
| 25 | EUCTR2016-004138-12-BE (EUCTR) | 27/11/2017 | 19/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Spain;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 26 | EUCTR2016-004138-12-GB (EUCTR) | 30/10/2017 | 17/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 27 | EUCTR2016-004138-12-NL (EUCTR) | 23/10/2017 | 24/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not Applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Latvia;Germany;Netherlands;United Kingdom | ||
| 28 | JPRN-UMIN000029113 | 2017/10/10 | 20/09/2017 | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis - Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | Patients with interstitial cystitis | Ingestion of test food including fermented buckwheat sprouts (12 weeks, 4 tablets / once a day) | Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka | Kageyama Hospital (Shizuoka city)Nakamura Hospital (Beppu city) | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan |
| 29 | NCT03282318 (ClinicalTrials.gov) | September 28, 2017 | 12/9/2017 | A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome;Interstitial Cystitis | Drug: ASP6294;Drug: Placebo | Astellas Pharma Europe B.V. | NULL | Completed | 18 Years | N/A | Female | 119 | Phase 2 | Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom |
| 30 | EUCTR2016-004138-12-PL (EUCTR) | 27/09/2017 | 19/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Belgium;Spain;Poland;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 31 | EUCTR2016-004138-12-DE (EUCTR) | 26/09/2017 | 10/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 32 | NCT03463499 (ClinicalTrials.gov) | September 22, 2017 | 25/2/2018 | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | Interstitial Cystitis | Drug: Hyaluronic Acid and Chondroitin Sulfate | Samsung Medical Center | NULL | Completed | 20 Years | N/A | All | 62 | N/A | Korea, Republic of |
| 33 | EUCTR2016-004138-12-ES (EUCTR) | 18/09/2017 | 18/09/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 34 | EUCTR2016-004138-12-HU (EUCTR) | 14/09/2017 | 12/07/2017 | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Czech Republic;Hungary;Spain;Poland;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 35 | EUCTR2016-004138-12-CZ (EUCTR) | 30/08/2017 | 13/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 36 | EUCTR2016-004138-12-LV (EUCTR) | 04/08/2017 | 25/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Germany;Latvia;United Kingdom | ||
| 37 | EUCTR2016-000906-12-NL (EUCTR) | 15/06/2017 | 19/07/2017 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by a 40-Week Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.1;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857 ;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 38 | JPRN-JapicCTI-173566 | 25/5/2017 | 20/04/2017 | Phase III study of KRP-116D | A Phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of KRP-116D in Japanese patients with interstitial cystisis. | Interstitial cystitis( IC ) | Intervention name : KRP-116D INN of the intervention : dimethyl sulfoxide Dosage And administration of the intervention : 50 mL intravesical instillation once every two weeks Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : 50 mL intravesical instillation once every two weeks | Kyorin Pharmaceutical Co.,LTD | NULL | complete | 20 | BOTH | 90 | Phase 3 | Japan | |
| 39 | EUCTR2016-000906-12-BE (EUCTR) | 24/04/2017 | 16/01/2017 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000017419;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 40 | NCT02870738 (ClinicalTrials.gov) | April 21, 2017 | 12/8/2016 | Bladder Directed vs. Pelvic Floor Therapy in IC/BPS | Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome | Cystitis, Interstitial;Painful Bladder Syndrome | Procedure: Pelvic Floor Physical Therapy;Drug: Bladder Instillations | William Beaumont Hospitals | Baylor College of Medicine | Recruiting | 18 Years | 85 Years | Female | 128 | Phase 2 | United States |
| 41 | NCT03104361 (ClinicalTrials.gov) | April 2017 | 3/4/2017 | Platelet-Rich Plasma (PRP) Injection in Treatment of Interstitial Cystitis | Intravesical Injections of Platelet-Rich Plasma (PRP) in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Clinical Trial | Interstitial Cystitis | Biological: Platelet-Rich Plasma | Buddhist Tzu Chi General Hospital | NULL | Not yet recruiting | 20 Years | N/A | All | 30 | Phase 1 | Taiwan |
| 42 | EUCTR2016-000906-12-ES (EUCTR) | 02/03/2017 | 16/01/2017 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by a 40-Week Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.1;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 43 | NCT03008382 (ClinicalTrials.gov) | March 1, 2017 | 28/12/2016 | Interstitial Cystitis: Examination of the Central Autonomic Network | Interstitial Cystitis: Examination of the Central Autonomic Network | Interstitial Cystitis/Painful Bladder Syndrome;Myofascial Pelvic Pain | Drug: Metoprolol Tartrate Oral Tablet;Drug: Placebo Oral Tablet | Medical College of Wisconsin | NorthShore University HealthSystem;Case Western Reserve University | Completed | 18 Years | 80 Years | Female | 80 | Phase 4 | United States |
| 44 | EUCTR2016-000906-12-GB (EUCTR) | 23/11/2016 | 19/08/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 45 | EUCTR2016-000906-12-LV (EUCTR) | 11/11/2016 | 01/08/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 46 | EUCTR2016-000906-12-CZ (EUCTR) | 07/11/2016 | 27/07/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Spain;Poland;Belgium;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 47 | EUCTR2016-000906-12-HU (EUCTR) | 23/09/2016 | 27/07/2016 | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods - The LEADERSHIP 301 Trial | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Czech Republic;Hungary;Canada;Spain;Belgium;Poland;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 48 | EUCTR2016-000906-12-DK (EUCTR) | 07/09/2016 | 19/07/2016 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom | ||
| 49 | NCT02787083 (ClinicalTrials.gov) | August 2016 | 23/5/2016 | A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis | A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis | Cystitis, Interstitial | Drug: Mirabegron;Drug: Placebo | Philadelphia Urosurgical Associates | Astellas Pharma Global Development, Inc. | Terminated | 18 Years | 95 Years | Female | 9 | Phase 3 | United States |
| 50 | JPRN-UMIN000027918 | 2016/07/01 | 25/06/2017 | Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis | Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis - Heparin-lidocaine intravesical injection therapy for interstitial cystitis | interstitial cystitis | heparin-lidocaine intravesical therapy | Department of Urology and Renal transplantation, Nagasaki University Hospital | NULL | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan |
| 51 | NCT02858453 (ClinicalTrials.gov) | July 2016 | 19/4/2016 | Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period | Interstitial Cystitis;Bladder Pain Syndrome;Painful Bladder Syndrome;Chronic Interstitial Cystitis | Drug: AQX-1125 100 mg;Drug: AQX-1125 200 mg;Drug: Placebo | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Unknown status | 18 Years | 80 Years | All | 433 | Phase 3 | United States;Belgium;Canada;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;Czech Republic |
| 52 | JPRN-UMIN000026714 | 2016/02/26 | 27/03/2017 | RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. | RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. - RCT study of bladder instillation therapy for refractory interstitial cystitis. | Interstitial cystitis | Treated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. | Department of Urology, Mitsui Memorial Hospital | NULL | Pending | 20years-old | Not applicable | Male and Female | 20 | Phase 2,3 | Japan |
| 53 | NCT02497976 (ClinicalTrials.gov) | December 15, 2015 | 10/7/2015 | Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis | Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis | Cystitis, Interstitial | Biological: Certolizumab pegol;Drug: Placebo | ICStudy, LLC | UCB Pharma | Completed | 18 Years | 65 Years | Female | 42 | Phase 3 | United States |
| 54 | EUCTR2015-004495-30-FI (EUCTR) | 14/12/2015 | 20/10/2015 | Safety of intravesical bladder instillations among patients with severe interstitial cystitis | Safety of intravesical bladder instillations among patients with severe interstitial cystitis | Interstitial cystitis and bladder pain syndrome MedDRA version: 18.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 18.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | Trade Name: SANDIMMUN INN or Proposed INN: CICLOSPORIN | Oulu University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
| 55 | NCT02591199 (ClinicalTrials.gov) | September 2015 | 28/10/2015 | Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Urigen | NULL | Terminated | 18 Years | N/A | All | 92 | Phase 2 | United States |
| 56 | NCT01393223 (ClinicalTrials.gov) | July 21, 2015 | 7/7/2011 | Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome | A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Interstitial Cystitis | Drug: LP-08 80mg;Drug: Normal saline;Drug: LP-08 20mg | Lipella Pharmaceuticals, Inc. | William Beaumont Hospitals | Completed | 18 Years | 70 Years | All | 21 | Phase 2 | United States |
| 57 | NCT02395042 (ClinicalTrials.gov) | April 15, 2015 | 17/3/2015 | A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions | A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions | Cystitis, Interstitial;Ulcer | Drug: LiRIS®;Drug: LiRIS Placebo | Allergan | NULL | Completed | 18 Years | N/A | Female | 59 | Phase 2 | United States;Canada |
| 58 | NCT03076762 (ClinicalTrials.gov) | March 2015 | 1/3/2017 | Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis | Comparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical Trial | Bladder Pain Syndrome | Drug: intravesical onabotulinumtoxinA injection | Buddhist Tzu Chi General Hospital | NULL | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | Taiwan |
| 59 | NCT02517996 (ClinicalTrials.gov) | February 2015 | 23/2/2015 | Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) | Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial | Interstitial Cystitis;Painful Bladder Syndrome | Drug: Lidocaine;Drug: Placebo | Johns Hopkins University | NULL | Terminated | 18 Years | N/A | Female | 18 | N/A | United States |
| 60 | NCT02297100 (ClinicalTrials.gov) | December 2014 | 30/9/2014 | Intravesicular Onabotulinumtoxin A in Interstitial Cystitis | The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4 | Interstitial Cystitis | Drug: Onabotulinumtoxin A;Procedure: injections upper aspect of trigone of urinary bladder;Procedure: injections on posterior bladder wall excluding the trigone | Wake Forest University Health Sciences | Allergan | Completed | 18 Years | 80 Years | Female | 27 | Phase 4 | United States |
| 61 | JPRN-UMIN000014860 | 2014/10/31 | 01/09/2014 | Efficacy and safety of intravesical administration of dimethyl sulfoxide (DMSO) in interstitial patients | Efficacy and safety of intravesical administration of dimethyl sulfoxide (DMSO) in interstitial patients - Efficacy and safety of intravesical administration of dimethyl sulfoxide (DMSO) in interstitial patients | interstitial cystitis | intravesical administration of DMSO | Urology, Hokkaido University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 10 | Not selected | Japan |
| 62 | NCT02247557 (ClinicalTrials.gov) | September 2014 | 15/9/2014 | Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis | Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective Study | Interstitial Cystitis | Drug: Liposome encapsulated BoNT-A;Drug: BOTOX 200U in normal saline;Drug: Normal saline | Buddhist Tzu Chi General Hospital | NULL | Completed | 20 Years | 80 Years | All | 90 | Phase 2 | Taiwan |
| 63 | JPRN-UMIN000009197 | 2014/07/01 | 01/11/2012 | Safety and efficacy of tramadol in the treatment of refractory pain of interstitial cystitis: a double-blind, placebo-controlled, randomized prospective study | Safety and efficacy of tramadol in the treatment of refractory pain of interstitial cystitis: a double-blind, placebo-controlled, randomized prospective study - The effect of tramadol on interstitial cystitis | interstitial cystitis | oral administration of Tramadol after randomization oral administration of placebo after randomization | Departmen of Urology, The University of Tokyo Hospital | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 90 | Not applicable | Japan |
| 64 | NCT01990898 (ClinicalTrials.gov) | November 2013 | 18/11/2013 | Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action | Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action | Interstitial Cystitis | Drug: Cyclosporine | The Cleveland Clinic | NULL | Completed | 18 Years | 80 Years | All | 26 | Phase 2 | United States |
| 65 | NCT01879683 (ClinicalTrials.gov) | July 2013 | 10/6/2013 | A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions | A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis | Chronic Interstitial Cystitis | Drug: LiRIS® 400 mg | Allergan | TARIS Biomedical, Inc. | Completed | 18 Years | N/A | Female | 10 | Phase 1 | United States |
| 66 | NCT01882543 (ClinicalTrials.gov) | June 2013 | 18/6/2013 | Efficacy and Safety of AQX-1125 in IC/BPS | A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway | Interstitial Cystitis;Bladder Pain Syndrome | Drug: AQX-1125;Drug: Placebo | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Completed | 18 Years | 75 Years | Female | 69 | Phase 2 | United States;Canada |
| 67 | EUCTR2011-004555-39-LT (EUCTR) | 10/05/2013 | 21/02/2013 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 68 | NCT01813565 (ClinicalTrials.gov) | March 20, 2013 | 11/3/2013 | The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome. | The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome. | Interstitial Cystitis | Drug: Hyaluronic acid/chondroitin sulfate | Asan Medical Center | NULL | Terminated | 20 Years | N/A | All | 15 | N/A | Korea, Republic of |
| 69 | NCT01824303 (ClinicalTrials.gov) | March 2013 | 31/3/2013 | Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension | Interstitial Cystitis | Drug: LiRIS 400 mg;Other: LiRIS Placebo | Allergan | TARIS Biomedical, Inc. | Terminated | 18 Years | N/A | Female | 31 | Phase 2 | United States;Canada |
| 70 | JPRN-JMA-IIA00113 | 27/02/2013 | 01/03/2013 | Multi-center clinical study on the effect of glycine for disorders of urine storage | Multi-center clinical study on the effect of glycine for disorders of urine storage | Overactive bladder, chronic prostatitis, interstitial cystitis, and nocturia | Intervention type:DRUG. Intervention1:glycine, Dose form:POWDER, Route of administration:ORAL, intended dose regimen:Oral administration of Glycine 3g, twice a day, for 8 weeks . Control intervention1:glucose, Dose form:POWDER, Route of administration:ORAL, Intended dose regimen:Oral administration of Glucose 3g, twice a day, for 8 weeks . | Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP) | Okinawa Kyodo Hospital, Kawahara Nephro-urology Clinic, Yamada Urologic Clinic, Akita Urologic Clinic, Kobe Medical Center, Kitanodai Clinic, Yokohama Motimachi Womens' Clinic LUNA, Nanbu Tokushukai Hospital, Okinawa Kokubu Hospital | Completed | >=20 YEARS | No Limit | BOTH | 160 | NOT APPLICABLE | Japan |
| 71 | NCT01048177 (ClinicalTrials.gov) | December 2012 | 11/1/2010 | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | Vulvodynia | Drug: Bladder instillation with heparin/ lidocaine | Scripps Health | NULL | Withdrawn | 18 Years | 80 Years | Female | 0 | Phase 2 | United States |
| 72 | NCT01969773 (ClinicalTrials.gov) | December 2012 | 22/10/2013 | Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment | Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial | Interstitial Cystitis | Drug: Botulinum toxin A;Drug: Normal saline instillation | Buddhist Tzu Chi General Hospital | NULL | Completed | 20 Years | 85 Years | All | 60 | Phase 2 | Taiwan |
| 73 | NCT01678911 (ClinicalTrials.gov) | August 2012 | 31/8/2012 | Efficacy of Gralise® for Chronic Pelvic Pain | Efficacy of Gralise® for Chronic Pelvic Pain | Irritable Bowel Syndrome;Ulcerative Colitis;Interstitial Cystitis;Prostatitis;Pelvic Pain | Drug: Gralise | Shirley Ryan AbilityLab | NULL | Terminated | 18 Years | N/A | All | 11 | Phase 4 | United States |
| 74 | JPRN-UMIN000008484 | 2012/07/23 | 20/07/2012 | a | a - a | Interstitial cystitis/ Hypersensitive bladder syndrome | Administration of mirabegron 50mg per day for four weeks. | Department of Urology, Graduate school of medicine, University of Tokyo | NULL | Pending | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan |
| 75 | EUCTR2011-004555-39-NL (EUCTR) | 05/07/2012 | 08/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 INN or Proposed INN: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 INN or Proposed INN: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 76 | NCT01731470 (ClinicalTrials.gov) | July 2012 | 15/11/2012 | Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) | Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) | Interstitial Cystitis;Pelvic Pain | Biological: Liposomes | Kenneth Peters, MD | William Beaumont Hospitals | Completed | 18 Years | N/A | All | 14 | N/A | United States |
| 77 | EUCTR2011-004555-39-PT (EUCTR) | 01/06/2012 | 05/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 78 | NCT01613586 (ClinicalTrials.gov) | May 31, 2012 | 5/6/2012 | A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis | Cystitis, Interstitial;Urinary Bladder Disease;Pain;Urologic Diseases | Drug: ASP3652;Drug: Placebo | Astellas Pharma Europe B.V. | NULL | Completed | 18 Years | N/A | Female | 287 | Phase 2 | Belgium;Czechia;Denmark;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Czech Republic |
| 79 | EUCTR2011-004555-39-PL (EUCTR) | 18/05/2012 | 11/04/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 80 | EUCTR2011-004555-39-BE (EUCTR) | 07/05/2012 | 19/01/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 81 | NCT02000401 (ClinicalTrials.gov) | May 2012 | 19/11/2013 | Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain | To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain | Interstitial Cystitis | Drug: Ketorolac Tromethamine | Citrus Valley Medical Research, Inc. | NULL | Completed | 18 Years | 64 Years | Female | 15 | Phase 4 | United States |
| 82 | EUCTR2011-004555-39-DE (EUCTR) | 30/04/2012 | 22/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Netherlands;Latvia | ||
| 83 | EUCTR2011-004555-39-ES (EUCTR) | 26/04/2012 | 06/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 300 | Phase 2 | Portugal;Russian Federation;Germany;Czech Republic;Netherlands;Denmark;Belgium;Romania;France;Spain;Latvia;Poland | ||
| 84 | EUCTR2011-004555-39-LV (EUCTR) | 20/04/2012 | 01/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 300 | Phase 2 | Portugal;Germany;Netherlands;France;Italy;Latvia;Czech Republic;Russian Federation;Belgium;Denmark;Romania;Spain;Poland | ||
| 85 | EUCTR2011-004555-39-DK (EUCTR) | 17/04/2012 | 17/04/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 86 | EUCTR2011-004555-39-CZ (EUCTR) | 13/04/2012 | 15/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 87 | NCT01569438 (ClinicalTrials.gov) | April 13, 2012 | 30/3/2012 | The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005) | A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Bladder Pain Syndrome | Drug: Gefapixant;Drug: Placebo | Afferent Pharmaceuticals, Inc. | NULL | Terminated | 18 Years | 80 Years | Female | 107 | Phase 2 | United States |
| 88 | NCT01559961 (ClinicalTrials.gov) | March 2012 | 15/3/2012 | Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis | Drug: TTI-1612 | Trillium Therapeutics Inc. | NULL | Completed | 18 Years | 65 Years | Female | 28 | Phase 1 | Canada |
| 89 | JPRN-UMIN000006387 | 2011/11/01 | 31/10/2011 | Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis | Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis - Heparin, lidocain and bicarbonate for interstitial cystitis | interstitital cystitis | Intravesical instillation of heparin, lidocain and bicarbonate | University of Tokushima | NULL | Pending | Not applicable | Not applicable | Male and Female | 30 | Phase 2 | Japan |
| 90 | NCT01475253 (ClinicalTrials.gov) | November 2011 | 3/11/2011 | Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis | A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label Extension | Interstitial Cystitis | Drug: Lidocaine Releasing Intravesical System - LiRIS®;Other: LiRIS Placebo;Procedure: Sham Cystoscopy Procedure | Allergan | TARIS Biomedical, Inc. | Terminated | 18 Years | N/A | Female | 104 | Phase 2 | United States;Canada |
| 91 | NCT05223244 (ClinicalTrials.gov) | October 1, 2011 | 24/1/2022 | Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC | Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective, Randomized Trial | Interstitial Cystitis;Painful Bladder Syndrome | Drug: bupivacaine, triamcinolone, and heparin (BTH);Drug: dimethyl sulfoxide (DMSO) | NorthShore University HealthSystem | NULL | Completed | 18 Years | N/A | Female | 83 | Phase 4 | NULL |
| 92 | NCT01378754 (ClinicalTrials.gov) | June 2011 | 8/6/2011 | Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia | A DOSE RANGING STUDY TO EVALUATE THE EFFECTIVENESS OF FOSPROPOFOL (LUSEDRA®) FOR INDUCTION OF ANESTHESIA FOR OUTPATIENT UROLOGIC HYDRODILATION THERAPY | Interstitial Cystitis | Drug: Fospropofol (Lusedra®) 6.5;Drug: Fospropofol (Lusedra®) 10;Drug: Fospropofol (Lusedra®) 12 | Grace Shih, MD | NULL | Withdrawn | 18 Years | 65 Years | Both | 0 | N/A | United States |
| 93 | NCT01295814 (ClinicalTrials.gov) | March 2011 | 14/2/2011 | Efficacy Study of Adalimumab to Treat Interstitial Cystitis | An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC) | Interstitial Cystitis | Drug: Adalimumab;Other: inactive drug | ICStudy, LLC | Abbott | Completed | 18 Years | 65 Years | All | 43 | Phase 3 | United States |
| 94 | EUCTR2010-021556-25-IT (EUCTR) | 24/02/2011 | 04/11/2010 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Interstitial Cystitis MedDRA version: 9.1;Level: HLGT;Classification code 10018188 | Trade Name: RIMSO 50 INN or Proposed INN: Dimethyl sulfoxide | IBSA | NULL | Not Recruiting | Female: yes Male: no | Phase 3 | Italy | |||
| 95 | NCT01197261 (ClinicalTrials.gov) | September 2010 | 7/9/2010 | OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) | An Exploratory, Randomised, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Assess the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets (OXN PR) Compared to Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome. | Interstitial Cystitis;Painful Bladder Syndrome;Pain | Drug: Oxycodone naloxone prolonged release tablets;Drug: Placebo tablets | Mundipharma Research GmbH & Co KG | NULL | Completed | 18 Years | N/A | Female | 120 | Phase 2 | Czechia;Germany;Hungary;Poland;United Kingdom;Czech Republic |
| 96 | EUCTR2009-018118-21-CZ (EUCTR) | 09/08/2010 | 10/06/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Hungary;Czech Republic;Germany;United Kingdom | |||
| 97 | EUCTR2009-018118-21-HU (EUCTR) | 04/08/2010 | 21/05/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Czech Republic;Hungary;Germany;United Kingdom | |||
| 98 | NCT01083979 (ClinicalTrials.gov) | August 2010 | 8/3/2010 | Intravesical Liposomes for Ulcerative Cystitis | Intravesical Liposomes for Ulcerative Cystitis | Interstitial Cystitis | Drug: Liposomes | Kenneth Peters, MD | NULL | Completed | 20 Years | N/A | All | 1 | N/A | United States |
| 99 | EUCTR2009-018118-21-GB (EUCTR) | 28/07/2010 | 11/06/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Czech Republic;Hungary;Germany;United Kingdom | ||
| 100 | NCT01150565 (ClinicalTrials.gov) | July 2010 | 23/6/2010 | Safety Study of LiRIS in Interstitial Cystitis (IC) Patients | Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: LiRIS low dose and LiRIS high dose | Allergan | TARIS Biomedical, Inc. | Completed | 18 Years | N/A | Female | 18 | Phase 1 | Canada |
| 101 | NCT00919802 (ClinicalTrials.gov) | June 2010 | 9/6/2009 | Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis | Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis | Interstitial Cystitis | Drug: Oxytocin;Other: Saline as a nasal spray | University of Alabama at Birmingham | NULL | Completed | 19 Years | 65 Years | All | 25 | Phase 4 | United States |
| 102 | EUCTR2009-014597-17-SE (EUCTR) | 03/05/2010 | 28/10/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Spain;Belgium;Germany;Sweden | ||
| 103 | NCT01195116 (ClinicalTrials.gov) | May 2010 | 13/8/2010 | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: Dexmedetomidine;Drug: Normal Saline | University of Rochester | NULL | Completed | 18 Years | N/A | All | 41 | Phase 4 | United States |
| 104 | NCT01060254 (ClinicalTrials.gov) | April 6, 2010 | 29/1/2010 | A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain | A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome | Cystitis, Interstitial;Urologic Diseases;Urinary Bladder Diseases;Cystitis | Drug: Placebo;Drug: JNJ-42160443 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | NULL | Terminated | 18 Years | 80 Years | All | 31 | Phase 2 | United States;Canada |
| 105 | EUCTR2009-014597-17-FI (EUCTR) | 24/03/2010 | 04/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 106 | EUCTR2009-014597-17-DE (EUCTR) | 19/03/2010 | 03/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Germany;Belgium;Spain;Sweden | ||
| 107 | EUCTR2009-014597-17-ES (EUCTR) | 08/02/2010 | 12/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vejiga dolorosa MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Belgium;Spain;Germany;Sweden | ||
| 108 | EUCTR2009-014597-17-SK (EUCTR) | 03/02/2010 | 11/02/2010 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 109 | NCT01069263 (ClinicalTrials.gov) | February 2010 | 10/1/2010 | Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis | Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial | Interstitial Cystitis | Other: Hyperbaric Oxygen Therapy;Drug: DMSO | Assaf-Harofeh Medical Center | NULL | Recruiting | 18 Years | 85 Years | Both | 60 | N/A | Israel |
| 110 | NCT00999518 (ClinicalTrials.gov) | January 22, 2010 | 20/10/2009 | A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS). | Cystitis, Interstitial | Biological: Tanezumab;Other: Placebo | Pfizer | NULL | Terminated | 18 Years | N/A | All | 205 | Phase 2 | United States;Belgium;Canada;Finland;Hong Kong;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Germany;India;South Africa |
| 111 | EUCTR2009-014597-17-BE (EUCTR) | 24/12/2009 | 09/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 112 | NCT01074567 (ClinicalTrials.gov) | December 2009 | 23/2/2010 | DMSO Efficacy in IC/PBS Patients During and After Treatment | Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment | Cystitis, Interstitial | Drug: DMSO cocktail | Assaf-Harofeh Medical Center | NULL | Recruiting | 18 Years | N/A | Female | 50 | N/A | Israel |
| 113 | NCT01030640 (ClinicalTrials.gov) | December 2009 | 9/12/2009 | Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected | A Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density Of Intraepidermal Nerve Fibers After A Single Subcutaneous Administration Of Tanezumab In Healthy Volunteers | Osteoarthritis Pain;Chronic Low Back Pain;Pain Due to Interstitial Cystitis | Other: placebo;Biological: tanezumab | Pfizer | NULL | Completed | 18 Years | 55 Years | Both | 28 | Phase 1 | United States |
| 114 | NCT01616992 (ClinicalTrials.gov) | September 2009 | 8/6/2012 | Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic Characteristics (ICEPAC) Study | Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic | Interstitial Cystitis/Painful Bladder Syndrome;Myofascial Pelvic Pain | Drug: Bupivacaine | Case Western Reserve University | NULL | Completed | 18 Years | 80 Years | Female | 200 | N/A | United States |
| 115 | NCT00919113 (ClinicalTrials.gov) | July 2009 | 11/6/2009 | Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome | A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome | Interstitial Cystitis;Painful Bladder Syndrome | Drug: 2% sodium chondroitin sulfate;Drug: Placebo | Watson Pharmaceuticals | NULL | Completed | 18 Years | N/A | Female | 98 | Phase 2 | United States |
| 116 | ChiCTR-TRC-13003938 | 2009-06-01 | 2013-05-17 | Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of randomized, double-blind, placebo-controlled trial | Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of randomized, double-blind, placebo-controlled trial | interstitial cystitis | group A:oral sildenafil;group B:oral placebo ; | The First Af?liated Hospital of Wenzhou Medical College | NULL | Completed | 35 | 55 | Both | group A:24;group B:24; | China | |
| 117 | NCT01294878 (ClinicalTrials.gov) | March 2009 | 11/2/2011 | Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome | Explorative Study on the Use of Omalizumab in Patients Suffering From Interstitial Cystitis/Painful Bladder Syndrome | Interstitial Cystitis;Painful Bladder Syndrome | Drug: omalizumab | IRCCS Policlinico S. Matteo | NULL | Completed | 18 Years | N/A | Female | 3 | Phase 3 | Italy |
| 118 | NCT00823030 (ClinicalTrials.gov) | January 2009 | 14/1/2009 | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Interstitial Cystitis | Procedure: Urodynamic study;Drug: Lidocaine;Other: Normal Saline | North Shore Long Island Jewish Health System | NULL | Withdrawn | 18 Years | 80 Years | Both | 0 | N/A | United States |
| 119 | EUCTR2008-002421-37-DK (EUCTR) | 13/11/2008 | 15/08/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD 0299685 Product Name: PD 0299685 | Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | Finland;Germany;Denmark;France | ||
| 120 | EUCTR2008-002421-37-FI (EUCTR) | 23/10/2008 | 02/09/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD 0299685 Product Name: PD 0299685 | Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | Finland;Germany;Denmark;France | ||
| 121 | EUCTR2008-002421-37-FR (EUCTR) | 07/10/2008 | 26/08/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS). MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD-0299685 Product Name: PD-0299685 | Pfizer Ltd;Ramsgate Road,Sandwich,Kent CT13 9NJ | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | France;Finland;Denmark;Germany | ||
| 122 | NCT00739739 (ClinicalTrials.gov) | August 2008 | 20/8/2008 | An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis | A Phase 2, 12 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof Of Concept Study Evaluating The Efficacy And Safety Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis/Painful Bladder Syndrome. | Interstitial Cystitis;Painful Bladder Syndrome | Drug: PD 0299685 at 15mg BID;Drug: PD 0299685 at 30mg BID;Drug: placebo for PD 0299685 | Pfizer | NULL | Completed | 18 Years | N/A | Both | 161 | Phase 2 | United States;Canada;Denmark;Finland;France;Germany |
| 123 | JPRN-UMIN000001253 | 2008/07/01 | 16/07/2008 | A randomized trial to asses the effects of hydrogen-rich dissolution water in patients with interstitial cystitis | Interstitial cystitis | The patients will be intervened with hydrogen dissolution water group (hydrogen group) 200ml every three times in a day in 2 months (56days). After that, the patients in hydrogen dissolution water group will be transferred to the additional intervention term after the end of intervention. And after that, the patients will be randomized to withdrawal terms for more 1 month with hydrogen dissolution water or with placebo water. The patients will be intervened with normal water (placebo group) 200ml every three times in a day in 2 months (56days) After that, the patients in placebo water group will be given hydrogen water for more 1 month. | Koushinkai Hospital | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 30 | Phase 2,3 | Japan | |
| 124 | EUCTR2008-001501-42-FI (EUCTR) | 15/05/2008 | 18/03/2008 | Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial Cystitis | Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial Cystitis | Painful bladder syndrome / interstitial cystitis (PBS/IC) MedDRA version: 1;Level: LLT;Classification code 10005063;Term: | Trade Name: Prograf INN or Proposed INN: TACROLIMUS | Jukka Sairanen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
| 125 | NCT00601484 (ClinicalTrials.gov) | March 2008 | 15/1/2008 | An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis | A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of PF-04383119 For The Treatment Of Pain Associated With Interstitial Cystitis | Cystitis, Interstitial | Drug: PF-04383119;Drug: Placebo | Pfizer | NULL | Completed | 18 Years | N/A | Both | 65 | Phase 2 | United States |
| 126 | EUCTR2007-005164-27-NL (EUCTR) | 22/02/2008 | 17/10/2007 | Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis | Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis | Interstitial Cystitis (IC) is a syndrome characterized by bladder pain associated with urgency, frequency, nocturia, dysuria and sterile urine. The patho-physiology remains largely unclear. No universally, effective, treatment exists. Botulinum toxin-A (BTX-A) inhibits the release of acetylcholine at the presynaptic cholinergic junction resulting in temporally muscle relaxation and bladder desensitisation. We explore the effects of intravesical injections with BTX-A in the treatment of IC. | Trade Name: Botox | research office urology VUmc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Netherlands | |||
| 127 | NCT00517868 (ClinicalTrials.gov) | August 2007 | 15/8/2007 | Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis | URG101 Pharmacodynamic and Safety Study: A Randomized, Double-blind, Placebo-controlled, Multi-center Cross-over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin. | Painful Bladder Syndrome;Interstitial Cystitis | Drug: URG101;Drug: Placebo | Urigen | NULL | Completed | 18 Years | N/A | All | 28 | Phase 2 | United States |
| 128 | NCT00451867 (ClinicalTrials.gov) | March 2007 | 23/3/2007 | A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . . | A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Mycophenolate Mofetil (CellCept) for the Treatment of Refractory Interstitial Cystitis (IC) | Interstitial Cystitis;Painful Bladder Syndrome | Drug: Mycophenolate Mofetil;Drug: Mycofenolate Mofetil (MMF);Drug: Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Terminated | 18 Years | N/A | Both | 210 | Phase 3 | United States;Canada |
| 129 | NCT00380783 (ClinicalTrials.gov) | October 2006 | 22/9/2006 | Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis | Cystitis, Interstitial | Drug: AGN 203818 | Allergan | NULL | Terminated | 18 Years | N/A | Female | 2 | Phase 2 | United States | |
| 130 | NCT00275379 (ClinicalTrials.gov) | August 2006 | 9/1/2006 | Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis | Cystitis, Interstitial | Drug: ERB-041 | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Withdrawn | 18 Years | N/A | Female | 0 | N/A | United States;Austria;Germany |
| 131 | NCT00317070 (ClinicalTrials.gov) | April 2006 | 20/4/2006 | Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC) | A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC) | Interstitial Cystitis;Bladder Diseases | Drug: dimethyl sulfoxide;Drug: IC Cocktail | Capital District Health Authority, Canada | NULL | Terminated | 18 Years | N/A | Both | 10 | Phase 2 | Canada |
| 132 | EUCTR2005-003367-23-DE (EUCTR) | 13/02/2006 | 23/11/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Germany;Sweden | ||
| 133 | EUCTR2005-003367-23-DK (EUCTR) | 06/02/2006 | 21/12/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Denmark;Germany;Sweden | ||
| 134 | EUCTR2005-003367-23-SE (EUCTR) | 01/02/2006 | 06/12/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Germany;Sweden | ||
| 135 | NCT00256542 (ClinicalTrials.gov) | January 2006 | 17/11/2005 | Study of U101 for Bladder Pain and/or Urgency | A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin | Pelvic Pain;Interstitial Cystitis;Bladder Diseases | Drug: Alkalinized Lidocaine-Heparin | Urigen | NULL | Completed | 18 Years | N/A | Both | 90 | Phase 2 | United States |
| 136 | EUCTR2005-000890-23-SE (EUCTR) | 13/10/2005 | 02/08/2005 | NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine. | NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine. | Interstitiell cystit | Trade Name: Sandimmun Neoral Product Name: Sandimmun Neoral INN or Proposed INN: Ciklosporin | Ingrid Ehrén | NULL | Not Recruiting | Female: yes Male: yes | 15 | Sweden | |||
| 137 | JPRN-UMIN000003172 | 2005/05/01 | 12/02/2010 | Clinacal study on the intravesical instillation of dimethylsulfoxide (DMSO) for the patients with interstitial cystitis | Clinacal study on the intravesical instillation of dimethylsulfoxide (DMSO) for the patients with interstitial cystitis - DMSO for interstitial cystitis | Interstitial cystitis | Intravesical instillation of DMSO | Deparment of Urology, Medical Science, University of Fukui | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 30 | Not applicable | Japan |
| 138 | NCT00295854 (ClinicalTrials.gov) | May 2005 | 22/2/2006 | Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis | A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: MN-001 BID;Drug: MN-001;Drug: Placebo | MediciNova | NULL | Completed | 18 Years | N/A | All | 296 | Phase 2 | United States |
| 139 | NCT00124306 (ClinicalTrials.gov) | February 2005 | 13/7/2005 | Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) | A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients | Bladder Diseases;Interstitial Cystitis | Drug: Amitriptyline;Other: Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | University of Pennsylvania | Completed | 18 Years | N/A | Both | 271 | Phase 3 | United States;Canada |
| 140 | JPRN-UMIN000027494 | 2004/07/20 | 25/05/2017 | Intravesical administration of Dimethyl sulfoxide(DMSO) for patients with Interstitial cystitis | Intravesical administration of Dimethyl sulfoxide(DMSO) for patients with Interstitial cystitis - Dimethyl sulfoxide(DMSO) for patients with Interstitial cystitis | Interstitial cystitis | Intravesical DMSO administration (50%, 50ml),2weeks every, 8 times | Department of Urology, Hamamatsu University School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Not applicable | Japan |
| 141 | NCT00194610 (ClinicalTrials.gov) | May 2004 | 13/9/2005 | Botox as a Treatment for Interstitial Cystitis in Women | Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial | Painful Bladder Syndrome;Interstitial Cystitis | Drug: Botox;Other: normal saline | University of Washington | Paul G. Allen Family Foundation | Completed | 18 Years | N/A | Female | 20 | Phase 4 | United States |
| 142 | NCT00086684 (ClinicalTrials.gov) | September 2003 | 7/7/2004 | Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis | Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis | Interstitial Cystitis | Drug: Pentosan polysulfate sodium 100 mg;Drug: Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | NULL | Terminated | 18 Years | N/A | All | 369 | Phase 4 | United States;Canada |
| 143 | NCT00004316 (ClinicalTrials.gov) | June 1995 | 18/10/1999 | Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis | Interstitial Cystitis;Vulvar Diseases | Drug: capsaicin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | University of Pittsburgh | Completed | 18 Years | N/A | Female | 139 | Phase 1/Phase 2 | NULL | |
| 144 | EUCTR2008-002421-37-DE (EUCTR) | 29/07/2008 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. MedDRA version: 9.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: PD 0299685 Product Name: PD 0299685 | Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 147 | Phase 2 | Finland;Germany;Denmark;France | |||
| 145 | EUCTR2009-018118-21-DE (EUCTR) | 10/05/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Czech Republic;Hungary;Germany;United Kingdom |